Redding, California, May 23, 2023 (GLOBE NEWSWIRE) -- According to a new market research report, ‘Point-of-Care Diagnostics Market by Application (Influenza, Pneumonia, HAI, Salmonellosis, Hepatitis, HIV, COVID, Pregnancy, Glucose Monitoring, Hematology, Tumor Marker, Urinalysis), Platform (LFA, Molecular), Sample, and End User - Global Forecast to 2030’, published by Meticulous Research®, the global point-of-care diagnostics market is expected to reach $43.1 billion by 2030, at a CAGR of 5.1% from 2023 to 2030
Point-of-care diagnostics, also known as bedside tests, are diagnostic tests performed on-site by healthcare professionals. These tests provide quick and accurate results without requiring samples to be sent to a laboratory. Point-of-care diagnostics products quickly determine a marker responsible for a certain disease. These tests can be used in various point-of-care settings such as physician offices, urgent care facilities, long-term care facilities, and nursing homes.
Download Free Sample Report Now: https://www.meticulousresearch.com/download-sample-report/cp_id=4871
The growth of the global point-of-care diagnostics market is mainly attributed to the rising rate of premature deaths because of chronic diseases, the rising geriatric population, and the integration of digital technologies in the healthcare sector. However, the high cost of the technology and the lower number of approvals for rapid tests is restraining the market. The increasing adoption of POC diagnostics by developing countries for advancement in their healthcare infrastructure provides market growth opportunities. The lack of awareness regarding the use of PoC devices is a major challenge for market growth.
Development Of CLIA-waived PoC Tests Drives the Point-of-care Diagnostics Market
In efforts to deliver effective diagnostic products, key market players are focused on simplifying and automating disease diagnosis and detection steps, revolutionizing disease diagnosis processes. For instance, manufacturers have started developing automated platforms that require minimal hands-on time by trained laboratory personnel; this has driven a shift in diagnostic testing from centralized laboratories to near-patient settings, such as hospital labs, physicians’ offices, hospital-outpatient departments, and home healthcare facilities. CLIA-waived tests enable testing in point-of-care settings.
These tests are simple procedures with an insignificant risk of erroneous results. Such tests can be used in various settings, including pharmacy-based clinics, urgent care centers, and hospitals. Waived tests that can be performed in physician offices include streptococcus testing, HIV testing, INR (coagulation) testing for Coumadin, and pregnancy testing. CLIA-waived tests speed up diagnosis and treatment, improving patients’ clinical outcomes.
The number of access points for CLIA-waived tests in facilities with a CLIA Certificate of Waiver has grown rapidly, from 67,294 in 1993 to 266,516 in March 2020. According to GenomeWeb data, the number of U.S. pharmacies certified to offer CLIA-waived testing increased by 28%, from 12,157 in 2019 to 15,671 in 2020.
Have Any Query? Ask To Analyst: https://www.meticulousresearch.com/speak-to-analyst/cp_id=4871
The global point-of-care diagnostics market is segmented by offering (consumables, instruments, and software and services); platform (lateral flow assays, molecular diagnostics, and other platform); application (blood glucose monitoring, infectious disease testing [parasitic infections testing, blood-borne infections testing {Hepatitis, HIV, other blood-borne infections}, respiratory infections testing {Influenza, Pneumonia, other respiratory infections testing}, healthcare-associated infection (HAI) testing, gastrointestinal infections testing {salmonellosis, E. Coli infections, other GI infections} other infectious diseases testing], COVID-19 testing, tumor/cancer markers testing, pregnancy and fertility testing [pregnancy testing, fertility testing], cardiac marker/cardiac metabolism testing, cholesterol/lipid profile testing, coagulation testing [prothrombin time (PT/INR) testing, activated clotting time (ACT/APTT) testing, other coagulation testing], hematology, drugs of abuse testing, urinalysis, other POC testing); sample type (blood sample, nasopharyngeal swab, urine sample, saliva sample, other sample types); end user (home care/self-testing, hospitals, physician offices & ambulatory care settings, diagnostics laboratories, and other end users), and geography. The study also evaluates industry competitors and analyzes their market share at the global and regional levels.
Based on offering, in 2023, the consumables segment is expected to account for the largest share of the point-of-care diagnostics market. Factors such as the increasing number of immunoassay and molecular diagnostics tests performed globally, leading to recurrent purchases of kits and reagents, rise in product approvals, and technological advancements in the products contribute to the large market share of this segment.
Based on platform, the LFA segment is projected to register the highest CAGR over the forecast period. The advantages of LFA-based rapid tests, such as their one-step process, long shelf life, higher portability & lower costs compared to laboratory-based tests, low sample quantities required for testing, recent technological developments, and the increasing use of lateral flow assay kits that can be used at home are factors driving the growth of this segment.
Based on application, in 2023, the blood glucose monitoring segment is expected to account for the largest share of the point-of-care diagnostics market. The rising prevalence of diabetes and the growing need for blood glucose monitoring is contributing to the largest market share of the segment. However, the tumor/cancer marker segment is projected to register the highest CAGR over the forecast period. The global burden of cancer is increasing rapidly, resulting in significant economic strain on countries worldwide. According to GLOBOCAN 2020, cancer incidence is projected to rise from 19.3 million in 2020 to 30.2 million in 2040. Furthermore, the mortality rate from cancer is estimated to increase from 9.9 million in 2020 to 16.3 million in 2040. The increasing incidence of cancer and developments in cancer marker testing is driving the growth of this market.
Quick Buy – Point-of-Care Diagnostics Market- Global Opportunity Analysis and Industry Forecast (2023-2030), Research Report: https://www.meticulousresearch.com/Checkout/65232676
Based on sample type, in 2023, the blood sample type segment is expected to account for the largest share of the global point-of-care diagnostics market. Blood sample analysis is the most widely used method for health monitoring. Point-of-care (PoC) devices enable blood analysis to be carried out at the patient's bedside at a faster rate and using low blood sample volume. PoC diagnosis using blood samples can be used for various tests, including blood glucose testing, blood gas and electrolytes analysis, thus driving the market growth.
Based on end-user, the home care/self-testing segment is projected to account for the highest CAGR during the forecast period. The growth of this segment is attributed to the wide availability of cost-effective point-of-care testing devices and the growing awareness of the importance of routine health monitoring. Moreover, home care settings are more cost-effective than hospital stays, considering factors such as costs of treatments, professionals, infrastructure, and other overheads.
Based on geography, North America is estimated to account for the largest share of the point-of-care diagnostics market in 2023. The large market share of North America can be attributed to the high number of laboratory tests performed annually in the region, the rising prevalence of chronic diseases coupled with growth in the aging population, and the rising number of inpatient hospitalizations drive the growth of the point-of-care diagnostics market in North America. However, Asia Pacific is expected to register the highest CAGR over the forecast period. Growth in the aging population, the rising prevalence of infectious & chronic diseases, and various government initiatives to promote health awareness drive the growth of the point-of-care diagnostics market in Asia-Pacific.
The report also includes an extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past years. The key players operating in the global point-of-care diagnostics market are Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), QuidelOrtho Corporation (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (U.S.), Becton, Dickinson and Company (U.S.), Chembio Diagnostics, Inc. (U.S.), EKF Diagnostics Holdings plc (U.K.), Trinity Biotech plc (Ireland), Werfen (Spain), Nova Biomedical (U.S.), Sekisui Diagnostics, LLC. (U.S.), Thermo Fisher Scientific Inc. (U.S.), and bioMérieux S.A. (France).
To gain more insights into the market with a detailed table of content and figures, click here: https://www.meticulousresearch.com/product/point-of-care-diagnostics-market-4871
Scope of the Report:
Point-of-care Diagnostics Market Assessment, by Offering
- Consumables
- Instruments
- Software and Services
Point-of-care Diagnostics Market Assessment, by Platform
- Lateral Flow Assays
- Molecular Diagnostics
- Other Platforms
(Other platforms majorly include coagulation tests, dipsticks, cholesterol and glucose monitoring systems, and other point-of-care diagnostic platforms)
Point-of-care Diagnostics Market Assessment, by Application
- Blood Glucose Monitoring
- Infectious Disease Testing
- Parasitic Infection Testing
- Blood-borne Infection Testing
- Hepatitis
- HIV
- Other Blood-borne Infections
- Respiratory Infections Testing
- Influenza
- Pneumonia
- Other Respiratory Infections Testing
- Healthcare-associated Infection (HAI) Testing
- Gastrointestinal (GI) Infection Testing
- Salmonellosis
- E. Coli Infections
- Other GI Infections
- Other Infectious Disease Testing
- COVID-19 Testing
- Tumor/Cancer Markers Testing
- Pregnancy And Fertility Testing
- Pregnancy Testing
- Fertility Testing
- Cardiac Marker/Cardiac Metabolism Testing
- Cholesterol/Lipid Profile Testing
- Coagulation Testing
- Prothrombin Time (PT/INR) Testing
- Activated Clotting Time (ACT/APTT) Testing
- Other Coagulation Testing
- Hematology
- Drugs Of Abuse Testing
- Urinalysis
- Other PoC Testing
(Other respiratory infections testing include strep infections and respiratory syncytial virus (RSV). Other GI infections include cholera, Helicobacter pylori (H. pylori), and campylobacteriosis. Other blood-borne diseases include syphilis and brucellosis. Other infectious disease testing includes meningitis, hand, foot, and mouth disease (HFMD), and mononucleosis. Other coagulation testing segment includes fibrinogen level and platelet count. Other PoC testing includes tropical diseases and sexually transmitted diseases)
Point-of-care Diagnostics Market Assessment, by Sample Type
- Blood Sample
- Nasopharyngeal Swab
- Urine Sample
- Saliva Sample
- Other Sample Types
(Other sample types include stool, cervical swab, buccal swab, hair, vaginal swab, and semen)
Point-of-care Diagnostics Market Assessment, by End User
- Hospitals
- Home care/self-testing
- Physician Offices & Ambulatory Care Settings
- Diagnostics Laboratories
- Other End Users
(Other end users include nursing homes, long-term care centers, pharmacies, urgent care facilities, schools, airports, hotels, and workplaces)
Point-of-care Diagnostics Market Assessment, by Geography
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa
Request Free Sample Report Now: https://www.meticulousresearch.com/request-sample-report/cp_id=4871
Related Reports:
Molecular Diagnostics Market by Product (Reagent & Kits, Systems, Software), Test Type (Lab, PoC), Technology (PCR, ISH, INAAT, Sequencing, Microarray), Application (Infectious Diseases, Oncology), End User (Hospital, Diagnostic Lab) - Global Forecast to 2030
https://www.meticulousresearch.com/product/molecular-diagnostics-market-5375
Rapid Diagnostics Market by Product (Kits [OTC, Professional], Readers), Platform (Lateral Flow, Serological, PCR), Application (Blood Glucose, Infectious Diseases, Pregnancy, Drugs of Abuse), End User (Hospitals, Diagnostic Labs, Home Care) - Global Forecast to 2029
https://www.meticulousresearch.com/product/rapid-diagnostics-market-5240
In-vitro Diagnostics Market by Product (Kits & Reagents, Software), Technology (Immunoassay [ELISA, Rapid test], Molecular Diagnostics [PCR, NGS], Biochemistry), Application (Infectious Diseases, Oncology, Cardiology), Diagnostic Approach (Lab, OTC, POC), End User - Global Forecast to 2030
https://www.meticulousresearch.com/product/ivd-market-4858
Tissue Diagnostics Market by Product Type (Antibodies, Kits, Reagents, Instruments [Slide Stainer, Scanner]), Technology (Digital Pathology, IHC, ISH, H&E Staining), Cancer Type (Breast, NSCLC, Colorectal, Prostate), and End user - Global Forecast to 2029
https://www.meticulousresearch.com/product/tissue-diagnostics-market-4971
Rapid Diagnostic Kits Market for Indian Ocean Region Countries (France, India, Australia, Indonesia, Singapore, Sri Lanka, Madagascar) by Product (Professional, OTC), Platform (Immunoassay, Molecular), Application (Infectious Diseases, Cardiac, Urinalysis, Cholesterol), End User (Hospital, Diagnostic Lab) - Forecast to 2029
Diagnostic Specialty Antibodies Market by Type (Primary, Secondary), Clonality (Monoclonal, Polyclonal), Technique (WB, Rapid Test, IHC, IP), Conjugate, and Application (Dengue, Malaria, Hepatitis, HIV, E. coli , Tuberculosis, Pneumonia, Cancer)- Forecast to 2029
https://www.meticulousresearch.com/product/diagnostic-specialty-antibodies-market-5241
In Vitro Diagnostic (IVD) Reagents Market by Type (Antibodies, Oligonucleotide, Nucleic Acid Probe), Technology (Immunoassay, Hematology, Microbiology), Use (Research, Analyte Specific Reagent), End User (IVD Manufacturer, Clinical Laboratory) - Global Forecast to 2027
https://www.meticulousresearch.com/product/in-vitro-diagnostic-reagents-market-5110
About Meticulous Research®
Meticulous Research® was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze, and present the critical market data with great attention to details. With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth.
Contact:
Mr. Khushal Bombe
Meticulous Market Research Inc.
1267 Willis St, Ste 200 Redding,
California, 96001, U.S.
USA: +1-646-781-8004
Europe : +44-203-868-8738
APAC: +91 744-7780008
Email- sales@meticulousresearch.com
Visit Our Website: https://www.meticulousresearch.com/
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Blog: https://meticulousblog.org/top-10-companies-in-point-of-care-diagnostics-market/
Content Source: https://www.meticulousresearch.com/pressrelease/299/point-of-care-diagnostics-market-2030
